Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Ophthalmol. 2007 Jun;91(6):804-7. Epub 2006 Dec 19.

Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).

Author information

  • 1Department of Ophthalmology, Tulane University Health Sciences Center, New Orleans, Louisiana, USA.

Abstract

AIM:

To evaluate the effect of topically administered bevacizumab (Avastin) on experimental corneal neovascularisation in rats.

METHODS:

Silver nitrate sticks (75% silver nitrate, 25% potassium nitrate) were used to perform chemical cauterisation on the corneas of 16 eyes from 16 male Long Evans rats. For the following 7 days, the 10 eyes in the treatment group were instilled with bevacizumab 4 mg/ml drops twice daily, whereas the 6 eyes in the control group received placebo (normal saline drops twice daily). Digital photographs of the cornea were analysed to determine the area of cornea covered by neovascularisation as a percentage of the total corneal area.

RESULTS:

In the bevacizumab-treated eyes, neovascularisation covered, on average, 38.2% (15.5%) (mean (SD)) of the corneal surface compared with 63.5% (5.0%) in the control group (p<0.02, Mann-Whitney U test).

CONCLUSION:

Topically administered bevacizumab (Avastin) at a concentration of 4 mg/ml limits corneal neovascularisation following chemical injury in the male Long Evans rat model.

PMID:
17179168
[PubMed - indexed for MEDLINE]
PMCID:
PMC1955569
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk